Therapeutics

While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.

The lawsuit states the $27.8 billion acquisition would allow Amgen to strengthen their drug portfolio and stifle drug competition in a bid to monopolize two fast-growing medications.

The company noted YUTIQ is used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and is the same as Alimera’s ILUVIEN.

The goal of the project is to encourage patients with Demodex blepharitis to visit an ophthalmologist.

According to researchers, these chronic, progressive retinal diseases, including retinitis pigmentosa, arise from genetic and environmental disruptions of cellular and tissue stability.

According to the company, the announcement represents the first FDA-approved, fixed-combination of tropicamide and phenylephrine for mydriasis.

Lowe is the VP, of Commercial Operations at Eyenovia, and discussed the FDA approval of MydCombi for mydriasis at the 2023 ASCRS annual meeting in San Diego.

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

The study, titled “A Clinical Registry Study of Glaucoma Medication Use in Patients with Mild Glaucoma Severity After MIGS,” will be presented Sunday by Michael Mbagwu, MD, at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, California.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego about the a new FDA clinical trial for a device called StableVisc being launched on the market by Bausch + Lomb.

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

In a presentation at the American Society for Cataract and Refractive Surgery annual meeting in San Diego, Ana Balbuena-Pareja, MSc, explained how cenegermin-bkbj ophthalmic solution 0.002% (Oxervate, Dompé) had a positive effect on corneal nerve regeneration and sensation in patients with neurotrophic keratitis.

APP13007 is used for the treatment of post-operative inflammation and pain following ocular surgery.

Horizon recently received an updated indication for TEPEZZA to specify its use in patients with TED, regardless of disease activity or duration, coming after the company released positive topline results from the phase four clinical trial of patients with chronic TED.

These three FDA-approved ophthalmic medicines, which are now commercially available under the Harrow umbrella, were among the five products that Harrow purchased in January of 2023.

Efavirenz boosts cholesterol turnover in retina, brain.

Analysis signals up to 59% risk reduction in rate of vision loss compared with sham treatment at 12 months.

Physician discusses clinical presentations, treatment options for 2 cases.

Therapies to target geographic atrophy are in sight.

According to data presented at the Association for Research in Vision and Ophthalmology Annual Meeting in New Orleans, post-hoc analysis from the GATHER trials, for the first time, signals that reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced geographic atrophy (GA) growth.

Pros and cons of anti-VEGF drugs and improved visualization of abnormalities in ROP.

The clearance of the Investigational New Drug Application will allow the company to initiate Phase 2 trials of the drug for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The ESSENCE-2 study showed a significantly greater reduction in the total corneal fluorescein staining (tCFS) score.

A study shows Atropine 0.01% eye drops decreased myopia progression in children over the course of 1 year.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

There have been 8 reported patients with vision loss as well as 4 reports of enucleation, or surgical removal of eyeball.

If approved, OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.

Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein.

Industry leaders view pegcetacoplan as most important retinal technology in 10 years.

The company plans to advance AAV-based gene therapy candidates toward IND studies on encouraging animal proof of concept data in Stargardt disease, X-linked retinoschisis, and autosomal dominant optic atrophy.